Abstract 764: Survival analysis for the elderly esophageal cancer patients (≥80 years) with surgery and non-surgery treatments

With the aging of population, the elderly esophageal cancer patients are increasing. However, the optimal treatment methods have not been well characterized for the elderly esophageal cancer patients because of that most randomized studies have excluded the elderly. The aim of this study was thus to analyze the outcomes of surgery and non-surgery therapy on the elderly patients aged 80 years or older with esophageal squamous cell carcinoma (ESCC) to provide more evidences for optimal treatment design on the elderly patient. The enrolled 1,143 ESCC cases in this study were from the ESCC database in Henan Key Laboratory for Esophageal Cancer Research. Of the 1,143 patients, there were 614 males with a mean age of 82.45±2.64 and 529 females with a mean age of 82.44±2.61. The age ranged from 80 to 96 years old at diagnosed. All the patients were confirmed as ESCC by histopathology. The patients were classified into four groups based on treatment methods, i.e., radical esophagectomy (group I), esophagectomy plus radiochemotherapy (group II), radiochemotherapy only (group III), and symptomatic treatment (group IV). Radical esophagectomy was performed on 304 patients (26.6%), including 134 males and 97 females. In addition, of the 304 patients with radical esophagectomy, there were 73 patients who were received radichemotherapy after surgery. 518 patients received only radiochemotherapy (45.3%). Radiochemotherapy included 50-60 Gy of radiation concurrent with or without 5-fluorouracil alone or combined with cisplatin. Moreover, there were 321 patients (28.1%) who did not receive either surgery or radiochemotherapy, but only with symptomatic treatment. The Kaplan-Meier analysis indicated that there was no significant difference in gender, age or histology between patients in the different groups. The overall 1-, 3- and 5-year survival rates were 56%, 31% and 19%, respectively, with a median survival time of 2.5 years. In group I, the overall 1-, 3- and 5-year survival rates were 68%, 48% and 30%, respectively, with a median survival time of 3.8 years. In group II, the overall 1-, 3- and 5-year survival rates were 48%, 32% and 14%, respectively, with a median survival time of 1.9 years. In group III, the overall 1-, 3- and 5-year survival rates were 58%, 28% and 18%, respectively, with a median survival time of 2.5 years. In group IV, the overall 1-, 3- and 5-year survival rates were 39%, 18% and 0.08%, respectively, with a median survival time of 1.6 years. The lo